 Ardelyx Inc NASDAQ: ARDX has amended its license agreement, initially executed in 2017, granting Kyowa Kirin exclusive rights to develop and commercialize Ardelyxs tenapanor for cardiorenal diseases, including hyperphosphatemia, in Japan. Under the agreement, considering. 